Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICL670 plus erythropoietin vs erythropoietin in low-/Int-1 risk MDS
CTR20150681Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2015
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of deferasirox, erythropoietin in myelodysplastic syndrome (MDS), sponsored by Novartis. Started Dec 2015; status: completed.
02
Drugs
deferasiroxerythropoietin
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on CTR20150681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150681.